Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
Rhea-AI Summary
Autonomix (NASDAQ: AMIX) presented post hoc subgroup data from its Proof-of-Concept 1 study at the 2026 ASCO GI symposium showing rapid, durable pain relief for pancreatic cancer patients across Stage 2–4 disease.
Key findings: responding patients showed marked pain reduction within 24 hours; at 7 days, 93.75% (N=16) improved from severe to mild/moderate pain; at 4–6 weeks about two-thirds (N=9) maintained mild/elimination pain; at 3 months no responding patients (N=6) reported severe pain and 50% maintained mild/elimination levels. The analysis included three patients with unknown stage and noted limited longer-term follow-up in some due to disease progression.
Positive
- Rapid pain reduction within 24 hours for responding patients
- 93.75% (N=16) improved from severe to mild/moderate pain at 7 days
- Approximately two-thirds (N=9) sustained mild/eliminated pain at 4–6 weeks
- At 3 months no responding patients (N=6) reported severe pain
Negative
- Post hoc subgroup analysis with small responder counts limits generalizability
- Longer-term follow-up limited for some patients due to disease progression
- Dataset includes 3 patients with unknown cancer stage, reducing clarity
News Market Reaction
On the day this news was published, AMIX gained 2.81%, reflecting a moderate positive market reaction. Argus tracked a peak move of +19.7% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $94K to the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMIX was up 0.77% pre‑news with low volume, while momentum scanners only flagged one sector peer (SSKN) moving down 4.48%. Broader medical device peers showed mixed moves, suggesting this update was likely stock‑specific rather than part of a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Patent grant | Positive | +8.3% | European patent granted for precision cardiac neuromodulation platform. |
| Dec 23 | Investor presentation | Neutral | -7.0% | CEO highlighted IP expansion and multi‑indication platform strategy. |
| Dec 18 | Conference selection | Positive | +4.6% | ASCO GI 2026 poster acceptance for pancreatic cancer pain data. |
| Nov 26 | CEO update | Positive | +10.2% | CEO Corner emphasized execution, IP protection, and pipeline expansion. |
| Nov 18 | Private placement | Negative | -17.4% | At‑the‑market priced <b>$5.0M</b> private placement with new warrants. |
Recent news reactions have mostly aligned with the nature of events: patent and clinical visibility updates tended to see positive responses, while financing activity coincided with notable share price pressure.
Over the last few months, Autonomix has balanced platform development, IP expansion, and financing. A European patent grant on Dec 30, 2025 and acceptance of the ASCO GI 2026 poster on Dec 18, 2025 both saw positive price moves. Investor‑facing CEO updates in November and December emphasized IP strength and multi‑indication strategy. By contrast, the $5.0 million private placement announced on Nov 18, 2025 triggered a sharp negative reaction. Today’s clinical subgroup data builds directly on the previously highlighted ASCO GI poster.
Regulatory & Risk Context
An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant shares for resale from a prior PIPE. While Autonomix receives no proceeds from resales, it could obtain up to $7.7 million if the common warrants are exercised in cash, which would also increase the share count materially over time.
Market Pulse Summary
This announcement details subgroup analyses from the PoC 1 study showing rapid and durable pancreatic cancer pain relief across stages, including late-stage patients. It builds on Autonomix’s prior ASCO GI 2026 poster and ongoing PoC program using transvascular RF denervation. Investors may track further clinical updates, durability beyond 3 months, and how these data support regulatory pathways. Capital structure remains an important backdrop given the registered resale of 13,504,998 warrant shares and prior going concern disclosures.
Key Terms
transvascular rf denervation medical
radiofrequency ablation medical
pancreatic adenocarcinoma medical
vas scale medical
post hoc subgroup analysis medical
AI-generated analysis. Not financial advice.
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options
THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company’s ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related pain.
The post hoc subgroup analysis expands upon previously reported findings from the Company’s ongoing Proof-of-Concept 1 (PoC 1) study, evaluating pancreatic cancer patients with severe baseline pain treated using a transvascular RF denervation platform. The analysis stratified outcomes by cancer stage, ranging from Stage 2 through Stage 4¹, and revealed consistent pain reduction regardless of disease severity.
Key Findings: Pain Relief Observed Across All Stages of Pancreatic Cancer
- Rapid onset effect: Responding patients demonstrated a marked reduction in average pain within 24 hours following the procedure.
- Early clinical impact: At 7-days post-procedure,
93.75% of responding patients (N=16) improved from severe pain to mild or moderate pain, with several achieving near-elimination levels of pain with a score of 1 or 0 on the VAS scale. - Sustained benefit: At 4–6-weeks post-procedure, approximately two-thirds of responding patients (N=9) maintained pain at mild or elimination levels.
- Durability through 3 months: At 3-months post-procedure, no responding patients (N=6) reported severe pain, and
50% maintained mild or eliminated pain levels. - Late-stage disease: Even among late-stage (Stage 4) cancer patients, meaningful improvement was observed. Several individuals with terminal disease reported a transition from severe to mild or moderate pain, at times even reporting near-elimination levels of pain relief. While disease progression limited longer-term follow-up in some cases, most reported substantial early improvement, underscoring the therapy’s potential palliative impact in advanced pancreatic cancer.
“Pancreatic cancer pain remains one of the most debilitating and undertreated aspects of oncology care,” commented Brad Hauser, President and Chief Executive Officer of Autonomix Medical. “Seeing patients move from severe pain to mild or near-elimination levels of pain, even in the most advanced stages of pancreatic cancer, is extraordinarily encouraging. These findings reinforce our belief that a targeted, nerve-based approach has the potential to provide meaningful relief when traditional pharmacologic and interventional options fall short.”
The subgroup findings were presented as part of Autonomix’s poster entitled “Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation”, during Poster Session B at ASCO GI 2026.
Additional details of the poster presentation:
Abstract Number: 693
Presenter: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
1. The dataset includes three patients with pancreatic cancer stage recorded as unknown.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What pain relief did Autonomix (AMIX) report at ASCO GI 2026?
How many AMIX patients showed improvement at 7 days and 3 months?
Did Autonomix (AMIX) show benefit for Stage 4 pancreatic cancer patients?
What are the main limitations of the AMIX PoC subgroup data presented at ASCO GI 2026?
What procedure was used in the Autonomix (AMIX) PoC 1 study?
